List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Extended Release of Pyridostigmine Bromide for Effectively Combating Nerve Agent Exposure

    SBC: Innosense Llc            Topic: CBD181004

    Chemical warfare agents such as the lethal nerve agent soman are a major source of risk to military personnel. Currently, pyridostigminebromide (PB) is the only FDA-approved pretreatment to counteract the effects of soman. The rationale behind PB administration is that it actsas a temporary inhibitor of AChE. This precludes nerve agents from irreversible inactivation of AChE, thereby mitigating th ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: Zymeron Corporation            Topic: CBD181004

    Given the unforeseen/unanticipated use of nerve agents in the battlefield and on the homeland, military personnel can benefit from this oncedaily pretreatment. It may also be desirable to pretreat certain medical and emergency aid personnel following a known/suspected nerveagent attack. Also, a novel, improved PB extended release formulations can be commercialized for the treatment of myasthenia g ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  3. Stable Formulation of Nerve Agent Intoxication Countermeasures

    SBC: Luna Innovations Incorporated            Topic: CBD181005

    In response to the defined need for minimizing the carry weight of combat teams while retaining capability, Luna Innovations is proposing thedevelopment of a stable formulation of atropine and scopolamine for use in an autoinjector to combat nerve agent intoxication. Thecombined formulation of atropine and scopolamine will allow for better treatment with more physiological coverage within the huma ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  4. Dual Formulation of Atropine and Scopolamine with Enhanced Stability

    SBC: Nano Terra, Inc.            Topic: CBD181005

    The standard US military treatment for nerve agent exposure is application of up to three autoinjectors, each containing atropine sulfate and2-pralidoxime, to counteract symptoms of nerve agent intoxication and restore acetylcholinesterase activity. This treatment increases survivalrates after nerve agent exposure, however, seizures resulting from nerve agent poisoning are a common symptom that ca ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  5. Dual Formulation of Atropine/Scopolamine with Enhanced Stability

    SBC: Cmc Pharmaceuticals, Inc.            Topic: CBD181005

    CMC Pharmaceuticals, Inc. (Cleveland, OH) is proposing developing a stable, combination product of two small molecule drug candidates as acounter measure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacologicalprofiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. It ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  6. Tomographic Nanoscopy for Pathogen Identification

    SBC: SOLID STATE SCIENTIFIC CORPORATION            Topic: CBD171003

    This effort will augment the capabilities of an existing all reflecting, confocal FTIR microscope to allow for digital holographic imaging as wellspectral content determination at video frame rates. The use of a dual beam frequency comb, with a beam path coincident with the pathrequired for the digital holographic imaging, will allow spectral determination of any organism being holographically ima ...

    SBIR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Process Development and Manufacture of an Antibody-based Therapy Against Sudan EbolaVirus

    SBC: BIOFACTURA, INC.            Topic: CBD171005

    Recently we have observed a massive outbreak of Ebola virus. This family of virus causes a significant bioterrorism threat due to the high levelof mortality, rate of transmissibility and the lack of an approved vaccine or therapy directed against it. The goal of this proposal is to develop,optimize and scale-up a mammalian cell culture-based bioprocess for the rapid manufacture of an antibody-base ...

    SBIR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government